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Induction of Peripheral Tolerance by Dendritic Cells.
 
Al-
though dendritic cells (DCs) are known to be critical for
inducing T cell immunity in immunized or infected indi-
viduals, it was recently proposed that DCs are also essential
to silence potentially pathogenic self-reactive T cells that
have escaped negative selection in the thymus (1, 2). One
important prediction of such a model would be that DCs
ingest, process, and present self-Ags in vivo under steady
state conditions. Three papers published in this issue exam-
ine the role of DCs in maintaining tolerance to self-Ags.
 
Self-Ags Are Captured and Processed by DCs in Healthy In-
dividuals.
 
Presentation of self-Ags by professional APCs
was first demonstrated in the thymus for Ags expressed by
cortical bone marrow–derived cells and for abundant solu-
ble Ags that could gain access to this organ by trafficking
through the blood (3). A number of studies have also
shown that APCs can process and present self-Ags to T
cells in the peripheral lymphoid organs. In healthy animals,
this often results in T cell tolerance. In pioneering studies,
Heath and colleagues have used RIP-OVA transgenic mice
in which OVA was selectively expressed in pancreatic 
 
 
 
cells and proximal kidney (4). To assess whether OVA was
processed and presented to T cells in vivo, these authors in-
jected RIP-OVA mice with OVA-specific TCR trans-
 
genic CD8
 
 
 
 T cells. Within 3 d after transfer, transgenic T
cells proliferated in the pancreatic and kidney draining LN
and were eventually deleted (5). T cell proliferation was
not observed in any other lymphoid organs further suggest-
ing that Ag presentation was occurring exclusively in the
draining LN. Somewhat similar findings were reported for
MHC class II–restricted epitopes in transgenic mice that
expressed either the SV40 large T Ag or the influenza hem-
agglutinin (HA) in pancreatic 
 
 
 
 cells (6, 7).
Although these studies have shown that self-Ags could
be processed and presented to T cells in the periphery, the
nature of the APCs that are involved remains unresolved.
Construction of bone marrow chimeras demonstrated that
self-Ags were processed and presented by bone marrow–
 
derived APCs. This was first shown for MHC class I–restricted
epitopes in RIP-OVA transgenic mice (4) and later on for
MHC class II–restricted epitopes (7). More recently, Kurts
and colleagues have created transgenic mice in which
MHC class I K
 
b
 
 molecules were selectively expressed in
CD11c
 
 
 
 cells (8). Elegant experiments using bone marrow
from these CD11c-K
 
b
 
 mice and RIP-OVA recipients
showed that CD11c
 
 
 
 cells are responsible for cross-presen-
tation of OVA in this animal model. In this issue, Belz and
colleagues have gone a step further by directly showing that
self-Ags can be processed and presented to CD8
 
 
 
 T cells by
a restricted subset of DCs (9). They have constructed trans-
genic mice, RIP-YSS, in which the yellow fluorescent
protein was fused to a class I epitope from Herpes simplex
virus-1 glycoprotein B (gB) and expressed under the con-
trol of the rat insulin promoter. Similar to other transgenic
strains, gB was readily processed and presented to CD8
 
 
 
 T
cells in pancreatic draining LN. To identify the nature of
the cross-presenting APCs, Belz et al. used a very sensitive
T cell hybridoma that produced 
 
 
 
-galactosidase in response
to stimulation with the MHC class I–restricted gB epitope.
Incubating this hybridoma with purified DC subsets pre-
pared from the pancreatic LN of RIP-YSS transgenic mice
revealed that CD8
 
 
 
 
 
, but not CD8
 
 
 
 
 
 DCs were the
cross-presenting APCs in vivo
 
.
 
 Also in this issue, Schei-
necker et al. provide another major break through by
showing that DCs are responsible for the processing of a
self-Ag in the stomach of healthy unmanipulated animals
(10). These authors have studied the gastric proton pump
H
 
 
 
/K
 
 
 
-ATPase whose expression is restricted to gastric
parietal cells. Using an mAb against the H
 
 
 
/K
 
 
 
-ATPase 
 
 
 
subunit, they could detect this self-Ag inside rare CD11c
 
 
 
cells in the gastric draining LN. Furthermore, CD11c
 
 
 
 cells
purified from the gastric LN induced the activation of a T
 
cell clone which was specific for a H
 
 
 
/K
 
 
 
-ATPase–
derived peptide bound to I-A
 
d
 
 molecules. T cell activation
was not inhibited by chloroquine, further suggesting that
 
DCs constitutively processed and presented H
 
 
 
/K
 
 
 
 ATPase
in vivo.
 
Tissue Damage Facilitates Capture and Presentation of Self-
Ags by DCs.
 
Although the new data from Heath and
Germain’s laboratories clearly show that DCs can process
and present self-Ags to CD4
 
 
 
 and CD8
 
 
 
 T cells in vivo,
the mechanisms by which Ags are captured in vivo have
not been elucidated. DCs may acquire self-Ags locally in
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peripheral tissues and subsequently migrate to the draining
LN. Alternatively, self-Ags may reach afferent lymphatic
vessels and be taken up by resident DCs in the draining
LN. This issue is even more complicated because soluble
and cell-associated Ags are likely to be captured by differ-
ent mechanisms. Scheinecker et al. (10) have also observed
physical contacts between CD8
 
 
 
 
 
 DCs and H
 
 
 
/K
 
 
 
-ATP-
ase-expressing parietal cells in the stomach of healthy
mice. Thus, there is at least some indirect evidence that
DCs constitutively residing in the stomach can acquire cell-
associated self-Ags in situ and subsequently transport them
to the gastric LN where they can be visualized in intracel-
lular vesicles within DCs. The question remains as to how
cell-associated Ags are taken up by DCs? Physiological in-
teractions between hematopoietic cells in the absence of
cell death can result in transfer of membrane components
between cells. DCs are highly interactive cells with exten-
sive membrane processes that facilitate cell clustering inter-
actions with other cells. Thus, it is theoretically possible
that DCs acquire Ags in the absence of apoptosis or necro-
sis of the donor cells. Indeed, experimental evidence sup-
porting this hypothesis has been reported in the case of pri-
mate cells for an endogeneous melanoma Ag (11). On the
other hand, apoptotic cell death facilitates the entry of self-
Ags into the cross-presentation pathway. This was first
demonstrated in vitro for both MHC class I– and MHC
class II–restricted epitopes (12) and has now been shown in
vivo (13–16). For example, cells that had been induced to
undergo apoptosis by exposure to osmotic shock were effi-
ciently taken up by splenic CD8
 
 
 
 
 
 DCs when injected in-
travenously into mice (14). In a perhaps more physiological
model, Kurts et al. have shown that peripheral Ags ex-
pressed at low levels did not enter the cross-presentation
pathway unless released by CTL-mediated tissue destruc-
tion (17, 18). Furthermore, the induction of pancreatic 
 
 
 
cell apoptosis promoted the presentation of islet Ags by
DCs (19).
 
What Is the Fate of Self-reactive T Cells That Have Encoun-
tered Self-Ags In Vivo?
 
Although DCs can readily capture
and present self-Ags to T cells, the immunological out-
come depends on different parameters including the phe-
notype of the DCs and the nature of the cytokine environ-
ment in which DC–T cell interactions occur. In the steady
state, that is in the absence of pathological or experimen-
tally induced tissue injury, presentation of self-Ags to
CD4
 
 
 
 and CD8
 
 
 
 T cell induces complete or partial T cell
tolerization through either deletion (5, 20) or induction of
unresponsiveness (1, 7). But what happens when parenchy-
mal cells are dying such as would happen during physiolog-
ical cell turnover (2, 15, 19) or as the result of tissue injury?
In this issue, Liu et al. have addressed this question by in-
jecting syngeneic animals with OVA-loaded splenocytes
that have been induced to die (21). In agreement with
other reports (13, 14, 22), dying cells were taken up by
CD8
 
 
 
 DCs in situ. In addition, ingestion and presentation
of cell-associated OVA resulted in the deletion of OVA-
specific CD8
 
 
 
 T cells and eventually in the induction of
immune tolerance. Thus, the capture of dying cells by DCs
 
in the steady state can lead to profound tolerance to cell-
associated Ags at least in the case of CD8
 
 
 
 self-reactive T
cells. Whether this also leads to the tolerization of CD4
 
 
 
 T
cells remains to be determined, but a recent study from our
laboratory suggests that this may well be the case (19).
 
What Is the Phenotype of the DCs That Present Self-Ags to T
Cells In Vivo?
 
Although DC subtypes have been defined
by multiple markers, the functional properties of these var-
ious DC populations remain a matter of controversy. At
least five phenotypically defined populations of DCs have
been reported in healthy mice, all of them express CD11c.
Three exist in the spleen (CD11b
 
 
 
CD4
 
 
 
, CD11b
 
 
 
CD4
 
 
 
,
CD11b
 
 
 
CD8
 
 
 
 
 
), whereas peripheral LN, Peyer’s patches,
and mesenteric LN contain two additional populations:
CD11b
 
low
 
CD4
 
 
 
CD8
 
 
 
 
 
 and langerin
 
 
 
 (23). Although
experiments performed under steady state conditions in
healthy animals have shown that all subpopulations arise
from independent precursors, it has also been reported that
CD8
 
 
 
 
 
 DCs could derive from CD8
 
 
 
 
 
 DCs by a matura-
tion process (23). With such a complicated situation, it is
not surprising that the nature of the DCs which present
self-Ags in vivo has remained controversial. In this respect,
the three papers published in this issue report different re-
sults, but this is not too surprising considering differences in
the experimental systems which have been studied. Thus,
Belz et al. found that CD8
 
 
 
 
 
 DCs were the only cells that
presented gB to CD8
 
 
 
 T cells in the pancreatic LN of their
transgenic mice. Likewise, splenic CD8
 
 
 
 
 
 but not CD8
 
 
 
 
 
DCs, presented OVA to CD8
 
 
 
 T cells in mice which had
been injected with OVA-loaded dying splenocytes (21).
On the other hand, both CD8
 
 
 
 
 
 and CD8
 
 
 
 
 
 DCs pre-
sented H
 
 
 
/K
 
 
 
-ATPase–derived MHC class II–restricted
epitopes in the gastric LN of BALB/c mice (10). Thus, al-
though the three papers being discussed here provide new
insights into the nature of the APCs which present self-Ags
to T cells, more experimental models will have to be stud-
ied to draw any definitive conclusions on the role of each
DC subset in the processing and the presentation of self-
Ags. Furthermore, because these three studies all relied on
ex vivo Ag presentation assays using sorted populations of
DCs, it was not possible to determine which cells within
each sorted population actually presented Ags and what was
their phenotype. This could possibly be done by using
mAbs reacting to specific peptide/MHC complexes (24–
27). Unfortunately, generating such reagents is not an easy
task. Furthermore, those which have been generated so far
often exhibit a relatively low avidity for their ligand, even-
tually precluding their use for identifying the APCs that
process and present Ags in vivo. Despite these limitations,
mAbs reacting to specific peptide–MHC complexes have
successfully been used to show that DCs from the T cell ar-
eas of LN express high levels of self-peptides bound to
MHC class II molecules (28, 29). The same mAbs have
been used to show that local expression of TNF-
 
 
 
 in pan-
creatic 
 
 
 
 cells promoted the presentation of self-Ags by
DCs in the islets (30). Molecular probes reacting to pep-
tide/MHC complexes may be used to identify and charac-
terize the APCs that present Ags to T cells. This is an 
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important issue because the outcome of DC–T cell interac-
tions is likely to be influenced by the phenotype of the
DCs. In this respect, recent experiments have provided di-
rect evidence that Ag-loaded immature DCs silence T cells
either by deleting them or by expanding regulatory T cells
(2). Such a phenomenon is likely to occur under steady
state conditions (1) and/or when cells undergo apoptosis
and are captured by DCs in the absence of inflammatory
cytokines (19, 21). In contrast to immature DCs, DCs ex-
pressing a more mature phenotype induce the development
of a functional immune response. This may occur in infec-
tious diseases, during powerful T cell immune responses
such as those observed in transplantation (31), contact al-
lergy (32), and autoimmunity (33), and upon immunologi-
cal manipulations such as the administration of agonistic
anti-CD40 mAbs (21).
 
What Next?
 
Further analyzing the role of DCs in the
maintenance of T cell tolerance to self-Ags may benefit
from the generation of new animal models. In this respect,
Brocker and colleagues have used the DC-specific CD11c
promoter to selectively direct the expression of specific
MHC molecules in DCs (8). Jung et al. have recently re-
ported a novel diphteria toxin-based system that allows the
inducible, short-term ablation of DCs in vivo (34). While
this latter experimental model has shown that DCs are re-
quired for the development of a cytotoxic T cell response
against 
 
Listeria monocytogenes
 
 and 
 
Plasmodium yoelii
 
, it may
also be useful for analyzing the role of DCs in the develop-
ment of T cell tolerance to self-Ags. Such studies may also
greatly benefit from the advent of new imaging techniques
such as two-photon laser scanning microscopy (TPLSM).
TPLSM provides the ability to track fluorescently labeled
cells over time deep within light-scattering tissue, while
largely avoiding the problems of bleaching and phototoxic-
ity associated with conventional confocal microscopy. In-
deed, TPLSM has recently been used to study the dynamic
of DC–T cell interactions in the LN of mice which had
been injected with Ag-loaded DCs (35, 36). There is little
doubt that TPLSM will soon be used to study interactions
between self-reactive T cells and DCs which present self-
Ags in vivo.
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